It remains to be determined if there is an association between TP53 status and clinical outcomes in HCC treated with yttrium-90 (Y90) transarterial radioembolization (TARE), which does not rely on ischemia as the primary mechanism of tumor cell death. Here, TP53 is linked to hepatocellular carcinoma.